United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total value of $3,367,980.00. Following the completion of the transaction, the executive vice president now directly owns 36,781 shares of the company's stock, valued at approximately $11,261,606.58. This represents a 23.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
United Therapeutics Price Performance
Shares of NASDAQ:UTHR traded up $2.27 during midday trading on Friday, reaching $281.16. 670,796 shares of the company's stock were exchanged, compared to its average volume of 453,276. The firm's 50 day simple moving average is $323.22 and its two-hundred day simple moving average is $351.14. United Therapeutics Co. has a fifty-two week low of $230.39 and a fifty-two week high of $417.82. The stock has a market cap of $12.63 billion, a price-to-earnings ratio of 12.35, a P/E/G ratio of 0.97 and a beta of 0.63.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating analysts' consensus estimates of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business had revenue of $735.90 million during the quarter, compared to analysts' expectations of $734.74 million. During the same period last year, the business earned $4.36 earnings per share. Equities research analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several brokerages recently issued reports on UTHR. StockNews.com cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. HC Wainwright reaffirmed a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. Finally, UBS Group lifted their price objective on United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat, United Therapeutics has an average rating of "Moderate Buy" and an average target price of $388.25.
Read Our Latest Research Report on UTHR
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the company. Milestone Asset Management LLC lifted its stake in United Therapeutics by 56.5% during the 4th quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company's stock worth $1,014,000 after acquiring an additional 1,037 shares in the last quarter. Korea Investment CORP lifted its position in shares of United Therapeutics by 6.2% during the fourth quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company's stock worth $13,863,000 after purchasing an additional 2,300 shares in the last quarter. Janney Montgomery Scott LLC lifted its position in shares of United Therapeutics by 9.1% during the fourth quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company's stock worth $3,326,000 after purchasing an additional 789 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of United Therapeutics by 35.4% in the third quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company's stock valued at $68,999,000 after purchasing an additional 50,291 shares in the last quarter. Finally, Burney Co. increased its stake in United Therapeutics by 113.3% during the 4th quarter. Burney Co. now owns 23,922 shares of the biotechnology company's stock worth $8,441,000 after buying an additional 12,705 shares during the period. 94.08% of the stock is currently owned by institutional investors and hedge funds.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
See Also
Before you consider United Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and United Therapeutics wasn't on the list.
While United Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
